You Position: Home > Paper
奈诺沙星在社区获得性肺炎抗菌治疗中的价值
( views:273, downloads:371 )
- Author:
- No author available
- Journal Title:
- Chinese Journal of Tuberculosis and Respiratory Diseases
- Issue:
- 10
- DOI:
- 10.3760/cma.j.issn.1001-0939.2017.10.015
- Key Word:
- No keyword available
Abstract： 目前,氟喹诺酮类药物对我国社区获得性肺炎(community acquired pneumonia,CAP)常见致病菌的敏感度仍然较高,且具有组织浓度高、口服生物利用度好、给药方便等特点,是CAP抗菌治疗的理想药物之一,但由于较多的药物不良反应、较强的抗MTB作用以及对肠杆菌科细菌较强的耐药诱导能力等因素,其临床应用受到了一定限制.
- [1]唐炯,程强,孙文霞.无氟喹诺酮类抗菌药研究进展[J].2016,(5).
- [2]朱德妹,吴培澄,胡付品,等.奈诺沙星体外抗菌作用研究[J].2015,(2).
- [3]Yu,J.,Wu,X.,Shi,Y.,etc.Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses[J].2012,32(7).
- [4]Chotikanatis,K.,Kohlhoff,S.A.,Hammerschlag,M.R..In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae[J].2014,58(3).
- [5]Kelly E, Dooley,Jonathan, Golub,Fernando S, Goes,etc.Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis.[J].2002,34(12).
- [6]Raewyn M. Poole.Nemonoxacin: First Global Approval[J].2014,74(12).
- [7]J J, Schentag,K K, Gilliland,J A, Paladino.What have we learned from pharmacokinetic and pharmacodynamic theories?[J].2001,32 Suppl 1.
- [8]Tan CK,Lai CC,Liao CH.Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis.[J].2009,64(2).
- [9]Hsu MC,Ho ML,Bester AJ,etc.Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia.[J].2010,54(10).
- [10]Cao,G.-Y.,Zhang,J.,Zhang,Y.-Y.,etc.Safety, tolerability, and pharmacokinetics of intravenous nemonoxacin in healthy Chinese volunteers[J].2014,58(10).
- [11]Bela, Kocsis,J, Domokos,D, Szabo.Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.[J].2016.
- [12]Dalhoff A,Schmitz FJ.In vitro antibacterial activity and pharmacodynamics of new quinolones.[J].2003,22(4).